“…In addition, in Jurkat cell line, only these two CAR Jurkat cell lines secreted IL-2 when co-cultured with CD19-positive cell line, NALM-6. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Compared with Mock T, the secretion of cytokines as IFN-γ, TNF-α, IL-6, IL-10 secreted by two CAR-Ts was increased, and the killing ability to c-Met positive GC cells was enhanced. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Adoptive cellular therapy using T cells with tumor specificity derived from either natural T cell receptors (TCRs) or an artificial chimeric antigen receptor (CAR) has reached late phase clinical testing, with two CAR T cell therapies achieving regulatory approval within the United States in 2017. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the European Medicines Agency. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…While their efficacy and safety profiles in patients with B-cell malignancies are comparable overall, the functional properties these two CAR designs impart upon engineered T cells differ significantly. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah(®) and Yescarta(®), have been approved by the Food and Drug Administration (FDA) for the treatment of lymphoblastic leukemia and B-cell lymphoma. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Chimeric Antigen Receptor (CAR)-T cell therapy is an exciting development in the field of cancer immunology, wherein immune T-cells from patients are collected, engineered to create ‘CAR’-T cells, and infused back into the same patient. Currently, two CAR-T-cell-based therapies, Tisagenlecleucel and Axicabtagene ciloleucel, are approved by FDA for the treatment of hematological malignancies, acute lymphoblastic leukemia and large B-cell lymphomas. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…These results have led to the recent approval of two CAR T‑cell products by the Food and Drug Administration (FDA) in the United States. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and tisagenlecleucel] have obtained US Food and Drug Administration approval for the treatment of refractory DLBCL after two lines of therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…These results have led to the regulatory approval of two CAR T cell approaches. Translation of this result to the solid tumor setting has been problematic until now. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Among them, CAR T-cell therapy emerges as one of the most promising treatments. In 2017, the first two CAR T-cell drugs, tisagenlecleucel and axicabtagene ciloleucel for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), respectively, were approved by the Food and Drug Administration (FDA). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Furthermore, through computational examination of the promoter region, we identified two CArG boxes, recognized as responsive elements to MADS transcription factors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We analyzed five risk-concerned product categories (anti-fogging, dye, disinfectant, repellent, and preservative products) for 13 products (three car anti-fogging products, a lens anti-fogging product, two car dye products, two drain disinfectants, an air conditioner disinfectant, a chlorine-based disinfectant, a fabric repellent, an insect repellent for food, and a wood preservative) considered to be of high risk in order to determine exposure factors via web surveys and estimation of amount of product. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Therefore, the approval of the first two CAR-Ts KYMRIAH and YESCARTA is highly encouraging for the field. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming into age. Two TRBAs and two CAR-T cell products have been approved by major regulatory agencies within the last ten years for the treatment of hematological cancers and an additional 53 TRBAs and 246 CAR cell constructs are in clinical trials today. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Standard deviations were in the order of a few millimeters. On the rover side, two car tests were performed in two different environments, one in an extra-urban environment with a long baseline of approximately 30 km in an open sky area with varying visibility and shielded locations, the other one in an urban area around a circle approximately 10 km in diameter with the presence of buildings and open sectors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RNA-sequencing further revealed vast disparities between the two CAR-T cell groups, with PB CAR-T cells exhibiting greater upregulation of cytokines, chemokines, and their receptors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We investigated the transcriptional profile of individual CD19 CAR-T infusion products using targeted single-cell RNA sequencing and multicolor flow cytometry. RESULTS: Two CAR-T infusions were not better than one in the settings used in this study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso